Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI).

Full DD Report for DMPI

You must become a subscriber to view this report.


Recent News from (NASDAQ: DMPI)

DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2018 Financial Results
VANCOUVER, British Columbia and MENLO PARK, Calif. , May, 17, 2018 /PRNewswire/ --  DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new cancer therapies, announced its financial results for the third ...
Source: PR Newswire
Date: May, 17 2018 05:30
DelMar Pharmaceuticals Presents Positive Updates on Two Ongoing Clinical Trials with VAL-083 for Treatment of MGMT-unmethylated GBM
VANCOUVER, British Columbia and MENLO PARK, Calif. , April 17, 2018 /PRNewswire/ --  DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced that ...
Source: PR Newswire
Date: April, 17 2018 14:00
DelMar Pharmaceuticals Announces Multiple Presentations at Annual Meeting of the American Association for Cancer Research
VANCOUVER, British Columbia and MENLO PARK, Calif. , April 16, 2018 /PRNewswire/ --  DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced four ...
Source: PR Newswire
Date: April, 16 2018 09:00
Today's Research Reports on Stocks to Watch: Lipocine and DelMar Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / February 28, 2018 / Lipocine shares were on fire after receiving an upgrade and a price target of $21 a share. Shares of DelMar Pharmaceuticals also soared higher despite any news but a report indicated the company has been granted a U.S. patent related to its VA...
Source: ACCESSWIRE IA
Date: February, 28 2018 08:20
Midday Gainers / Losers (2/27/2018)
Gainers: MNK +22% . DMPI +22% . I +19% . PLOW +17% . LXU +16% . NGHC +15% . LPCN +14% . DDS +14% . YECO +12% . SRDX +12% . More news on: Mallinckrodt PLC, DelMar Pharmaceuticals, Inc., Intelsat SA, Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: February, 27 2018 12:45
DelMar Pharmaceuticals' (DMPI) Management on Q2 2018 Results - Earnings Call Transcript
DelMar Pharmaceuticals, Inc. (DMPI) Q2 2018 Earnings Conference Call February 20, 2018 4:30 PM ET Executives Saiid Zarrabian – President and Chief Executive Officer Dennis Brown – Chief Scientific Officer Scott Praill – Chief Financial Officer Analysts ...
Source: SeekingAlpha
Date: February, 20 2018 20:27
Midday Gainers / Losers (2/15/2018)
Gainers: MBRX +61% . AMAG +29% . GLMD +24% . SEDG +20% . LBCC +21% . BBW +17% . COOL +17% . ANDE +16% . WBAI +15% . ATRS +15% . More news on: Moleculin Biotech, Inc., AMAG Pharmaceuticals, Inc., Galmed Pharmaceuticals Ltd., Stocks on the move, , Read mo...
Source: SeekingAlpha
Date: February, 15 2018 12:40
DelMar Pharmaceuticals beats by $0.01
DelMar Pharmaceuticals (NASDAQ: DMPI ): Q2 EPS of -$0.14 beats by $0.01 . Cash of $11M. Press Release More news on: DelMar Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, ,
Source: SeekingAlpha
Date: February, 14 2018 17:57
DelMar Pharmaceuticals Announces Second Quarter Fiscal Year 2018 Financial Results
VANCOUVER, British Columbia and MENLO PARK, Calif. , Feb. 14, 2018 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new cancer therapies, announced its financial results for the second qu...
Source: PR Newswire
Date: February, 14 2018 17:39
Your Daily Pharma Scoop: Portola BLA Review Process Delayed, DelMar Soars, Alexion Gets Nod For Soliris In Japan
Analysis of top Seeking Alpha coverage: Portola Today we will discuss the implications of the delay in the review of Portola’s ( PTLA ) AndexXa BLA. The news sent PTLA shares down more than 10% on Tuesday. Portola closed 10.68% lower on Tuesday at $49. Despite the sell-off on Tu...
Source: SeekingAlpha
Date: December, 28 2017 01:42

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-140.460.44010.460.4001157,252
2018-08-130.51010.44750.52870.3257459,715
2018-08-100.52010.5151510.530.50879,919
2018-08-090.55720.53030.5630820.530360,740
2018-08-080.57210.550.57210.513240,591

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1426,93162,35743.1884Short
2018-08-1358,554127,62145.8812Short
2018-08-107,52015,19349.4965Short
2018-08-0910,44217,18360.7694Short
2018-08-081,4316,93220.6434Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on DMPI.


About DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI)

Logo for DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI)

DelMar Pharmaceuticals, Inc. is a clinical and commercial stage drug development company with a focus on the treatment of cancer.

 

Contact Information

 

 

Current Management

  • Jeffrey Bacha / CEO, President
  • Scott Praill / CFO
  • Dennis Brown / Chief Scientific Officer
  • Jeffrey Bacha / Chairman
  • John Kearns Bell /
  • Dennis Brown /
  • Lynda Cranston /
  • Erich Mohr /
  • Robert Toth /

Current Share Structure

  • Market Cap: $24,997,369 - 03/09/2018
  • Authorized: 50,000,000 - 06/20/2016
  • Issue and Outstanding: 21,927,517 - 02/13/2018

 


Recent Filings from (NASDAQ: DMPI)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 17 2018
Amendment to a previously filed 8-K
Filing Type: 8-K/AFiling Source: edgar
Filing Date: May, 17 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 15 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 11 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 11 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 13 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 13 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: March, 09 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: March, 09 2018
Preliminary proxy statement providing notification matters to be brought to a vote
Filing Type: PRE 14AFiling Source: edgar
Filing Date: February, 22 2018

 

 


Daily Technical Chart for (NASDAQ: DMPI)

Daily Technical Chart for (NASDAQ: DMPI)


Stay tuned for daily updates and more on (NASDAQ: DMPI)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: DMPI)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in DMPI is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of DMPI and does not buy, sell, or trade any shares of DMPI. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/